RecruitingGeneralized Anxiety Disorder
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
Eligible age
18–74 yrs
Accepts
All genders
Locations
14 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
Sponsor: Reunion Neuroscience Inc
You may qualify if…
- ✓ Has Generalized Anxiety Disorder as defined by DSM-5-TR
- ✓ If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant.
- ✓ Is willing and able to comply with the conditions and requirements of the study
You may not qualify if…
- ✕ Has a significant risk of suicide
- ✕ Has an active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder
- ✕ Has other concurrent psychiatric disorders that is the primary disorder.
- ✕ Has other medically significant conditions rendering unsuitability for the study
- ✕ Has used or will need to use prohibited medications or therapies
- ✕ Has a known sensitivity or intolerance to study intervention or potential rescue medications
Where it's recruiting
Source: ClinicalTrials.gov · NCT07489651 · last updated 2026-06-26